Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | DBH | P09172 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31151091 | 0.82 | CSNK2A1 (0.42) | FFAR4FFAR1CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL334154 | 0.82 | FFAR4 (0.40) | TTRFFAR4FFAR1CRHBPCRHR2 | |
| SCHEMBL4575838 | 0.81 | TTR (0.54) | TTRCRHBPCRHR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4267521 | 0.81 | TTR (0.41) | TTRFFAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL4255534 | 0.81 | TTR (0.41) | TTRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL27628630 | 0.80 | TTR (0.39) | TTRFFAR4FFAR1CRHBPCRHR2 | |
| SCHEMBL4754427 | 0.79 | FFAR4 (0.38) | FFAR4FFAR1CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL13342977 | 0.78 | SCN4A (0.50) | SMN1; SMN2ALDH1A1MEN1KMT2ASCN4A | |
| SCHEMBL31511767 | 0.77 | SLC6A4 (0.42) | TTRFFAR4FFAR1ALDH1A1MEN1 | |
| SCHEMBL29601399 | 0.77 | HPGD (0.50) | SMN1; SMN2ALDH1A1MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101296914-B | Derivatives with PPAR agonist activity | SHIONOGI & CO | 2012-07-18 | — | — | CN | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| CN-101296914-A | Derivatives with PPAR agonist activity | SHIONOGI & CO (JP) | 2008-10-29 | — | — | CN | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | TTR 3141/4885FFAR4 35/4885FFAR1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.